// App-Quantinova.ai

[AB0738] : SECUKINUMAB REDUCES HSCRP LEVELS IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND CONCOMITANT PSORIATIC ARTHRITIS: A SUB-ANALYSIS FROM THE PHASE 3 ERASURE STUDY

Researchers

Presenter

  • A. Gottlieb

Principal Investigators

  • B. Sigurgeirsson

  • A. Blauvelt

  • Y. Gong

  • C. Papavassilis

  • S. Mpofu

Medical Centers

  • Tufts Medical Center, Boston, United States

  • Department of Dermatology, University of Iceland, Iceland

  • Oregon Medical Research Center, Portland, United States

Locations

  • United States

  • Iceland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved